Glaukos Corporation Glaukos Corporation

Glaukos Corporation

GKOS

Rank in Stocks #2116
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Share Price
$164.43
Last synced: 2026-10-16
Market Cap
$9.70B
Change (1 day)
-0.95%
Change (1 year)
88.63%
Country
US
Trade Glaukos Corporation (GKOS)

Category

Healthcare
Dividend history for Glaukos Corporation (GKOS)
Glaukos Corporation (stock symbol: GKOS) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Glaukos Corporation (GKOS) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
173.00%
US
178.00%
IE
85.00%
US
0.00%
US
0.00%
DE